title: Remission induction and maintenance modalities in acute myeloid leukemia: a multicenter randomized study.
authors.forename: M
authors.initials: M
authors.lastname: Marty
authors.forename: E
authors.initials: E
authors.lastname: Lepage
authors.forename: H
authors.initials: H
authors.lastname: Guy
authors.forename: D
authors.initials: D
authors.lastname: Bordessoule
authors.forename: B
authors.initials: B
authors.lastname: Desablens
authors.forename: J L
authors.initials: JL
authors.lastname: Harousseau
authors.forename: F
authors.initials: F
authors.lastname: Guilhot
authors.forename: G
authors.initials: G
authors.lastname: Leverger
authors.forename: G
authors.initials: G
authors.lastname: Schaison
authors.forename: M
authors.initials: M
authors.lastname: Boiron
mesh_terms: D000677:Amsacrine / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003520:Cyclophosphamide / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage; D003630:Daunorubicin / Q000008:administration & dosage / Q000031:analogs & derivatives; D005602:France; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D011897:Random Allocation; D012074:Remission Induction; D013997:Time Factors
chemical_list: D000677:Amsacrine; D003561:Cytarabine; D003520:Cyclophosphamide; C002205:zorubicin; D003630:Daunorubicin